Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. (SYRE) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
syre · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Spyre Therapeutics, Inc. (SYRE) measures how much investors pay for each dollar of the company's trailing earnings. SYRE's current PE ratio of N/A is calculated by dividing its stock price of $72.00 by its TTM earnings per share of -$0.52.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2013 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Spyre Therapeutics, Inc.You SYRE | $4.3B | N/A | — | -$0.52 |
 AbCellera Biologics Inc. ABCL | $1.7B | N/A | — | -$0.49 |
 Ardelyx, Inc. ARDX | $1.4B | N/A | — | -$0.26 |
 Celldex Therapeutics, Inc. CLDX | $1.9B | N/A | — | -$3.89 |
 Immunome, Inc. IMNM | $1.8B | N/A | — | -$2.43 |
 Maze Therapeutics, Inc. MAZE | $1.3B | N/A | — | -$3.05 |
 Intellia Therapeutics, Inc. NTLA | $1.5B | N/A | — | -$3.81 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.45 | — | |
2024-12-31 FY2024 | — | $-4.42 | — | |
2023-12-31 FY2023 | — | $-49.12 | — | |
2022-12-31 FY2022 | — | $-24.86 | — | |
2021-12-31 FY2021 | — | $-25.02 | — | |
2020-12-31 FY2020 | — | $-37.89 | — | |
2019-12-31 FY2019 | — | $-61.23 | — | |
2018-12-31 FY2018 | — | $-53.25 | — | |
2017-12-31 FY2017 | — | $-45.01 | — | |
2016-12-31 FY2016 | — | $-55.40 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Spyre Therapeutics, Inc. (SYRE) measures how much investors pay for each dollar of the company's trailing earnings. SYRE's current PE ratio of N/A is calculated by dividing its stock price of $72.00 by its TTM earnings per share of -$0.52.
Frequently asked questions
SYRE pe ratio · 6 questionsSYRE's current PE ratio is N/A as of 2026-06-08, based on a stock price of $72.00 and TTM EPS of -$0.52. Data sourced from Financial Modeling Prep via SYRE's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Spyre Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08